

Systemic Alterations of Wnt Inhibitors in Patients with Prostate Cancer and Bone Metastases. Aufderklamm, S. et al. *Disease Markers*. 2018, 2018, 1874598.

<https://doi.org/10.1155/2018/1874598> PMID: 30116403; PMCID: PMC6079590

LRP5 gene polymorphisms and radiographic joint damage in rheumatoid arthritis patients. Bernardes, M. et al. *Osteoporosis International*. 2018.

<https://doi.org/10.1007/s00198-018-4625-3>

Association of Wnt Inhibitors, Bone Mineral Density and Lifestyle Parameters in Women with Breast Cancer Treated with Anastrozole Therapy. Bojanić, K. et al. *Journal of Clinical Medicine*. 2018, 7(9).

<https://doi.org/10.3390/jcm7090287> PMID: 30227689; PMCID: PMC6162798

Study of bone metabolism and angiogenesis in patients undergoing high-dose chemotherapy/autologous hematopoietic stem cell transplantation. Boutsikas, G. et al. *European Journal of Haematology*. 2018, 100(2), 131–139.

<https://doi.org/10.1111/ejh.12990>

Pulsed electromagnetic fields modulate bone metabolism via RANKL/OPG and Wnt/ β -catenin pathways in women with postmenopausal osteoporosis: A pilot study. Catalano, Antonino et al. *Bone*. 2018, 116, 42–46.

<https://doi.org/10.1016/j.bone.2018.07.010>

Bone, muscle, and metabolic parameters predict survival in patients with synchronous bone metastases from lung cancers. Chambard, L. et al. *Bone*. 2018, 108, 202–209.

<https://doi.org/10.1016/j.bone.2018.01.004>

Serum levels of sclerostin as a potential biomarker in central arterial stiffness among hypertensive patients. Chang, Y.-C. et al. *BMC Cardiovascular Disorders*. 2018, 18(1), 214.

<https://doi.org/10.1186/s12872-018-0955-5> PMID: 30482161

Bone Geometry, Quality, and Bone Markers in Children with Type 1 Diabetes Mellitus. Franceschi, R. et al. *Calcified Tissue International*. 2018, 102(6), 657–665.

<https://doi.org/10.1007/s00223-017-0381-1>

Effect of Teriparatide Treatment on Circulating Periostin and Its Relationship to Regulators of Bone Formation and BMD in Postmenopausal Women With Osteoporosis. Gossiel, F. et al. *The Journal of Clinical Endocrinology & Metabolism*. 2018, 103(4), 1302–1309.

<https://doi.org/10.1210/jc.2017-00283>

Bone metabolism in patients with anorexia nervosa and amenorrhoea. Idolazzi, L. et al. *Eating and Weight Disorders - Studies on Anorexia, Bulimia and Obesity*. 2018, 23(2), 255–261.

<https://doi.org/10.1007/s40519-016-0337-x>

Do hypoxia and L-mimosine modulate sclerostin and dickkopf-1 production in human dental pulp-derived cells? Insights from monolayer, spheroid and tooth slice cultures. Janjić, K. et al. *BMC Oral Health*. 2018, 18(1).

<https://doi.org/10.1186/s12903-018-0492-8>

Glucocorticoid therapy causes contradictory changes of serum Wnt signaling-related molecules in systemic autoimmune diseases. Kawazoe, M. et al. *Clinical Rheumatology*. 2018, 37(8), 2169–2178.

<https://doi.org/10.1007/s10067-017-3689-3>

Myostatin and other musculoskeletal markers in lung transplant recipients.

Kerschman-Schindl, K. et al. *Clinical and Experimental Medicine*. 2018.

<https://doi.org/10.1007/s10238-018-0532-3> PMID: 30317402

Rheumatoid arthritis in remission : Decreased myostatin and increased serum levels of periostin. Kerschán-Schindl, K. et al. *Wiener Klinische Wochenschrift*. 2018.

<https://doi.org/10.1007/s00508-018-1386-0> PMID: 30171335

The serum sclerostin level is positively associated with the aortic augmentation index in patients on peritoneal dialysis. Lin, L. et al. *Tzu Chi Medical Journal*. 2018, 0(0), 0.

https://doi.org/10.4103/tcmj.tcmj_90_18

DKK1 and sclerostin are early markers of relapse in multiple myeloma. Mabile, C. et al. *Bone*. 2018, 113, 114–117.

<https://doi.org/10.1016/j.bone.2017.10.004>

Two-year cortical and trabecular bone loss in CKD-5D: biochemical and clinical predictors. Malluche, H. H. et al. *Osteoporosis International*. 2018, 29(1), 125–134.

<https://doi.org/10.1007/s00198-017-4228-4>

Association between non-alcoholic fatty liver disease and bone turnover biomarkers in post-menopausal women with type 2 diabetes. Mantovani, A. et al. *Diabetes & Metabolism*. 2018.

<https://doi.org/10.1016/j.diabet.2018.10.001> PMID: 30315891

Parathyroid hormone is a determinant of serum Dickkopf-1 levels in ankylosing spondylitis. Orsolini, G. et al. *Clinical Rheumatology*. 2018.

<https://doi.org/10.1007/s10067-018-4205-0>

Differential effects of high-fat diet and exercise training on bone and energy metabolism. Picke, A.-K. et al. *Bone*. 2018, 116, 120–134.

<https://doi.org/10.1016/j.bone.2018.07.015>

Sclerostin rather than Dickkopf-1 is associated with mSASSS but not with disease activity score in patients with ankylosing spondylitis. Sun, W. et al. *Clinical Rheumatology*. 2018.

<https://doi.org/10.1007/s10067-018-4356-z> PMID: 30443790

Bone metabolism markers and angiogenic cytokines as regulators of human hematopoietic stem cell mobilization. Tsirkinidis, P. et al. *Journal of Bone and Mineral Metabolism*. 2018, 36(4), 399–409.

<https://doi.org/10.1007/s00774-017-0853-4>

Denosumab effects on bone density and turnover in postmenopausal women with low bone mass with or without previous treatment. Tsourdi, E. et al. *Bone*. 2018, 120, 44–49.

<https://doi.org/10.1016/j.bone.2018.10.001> PMID: 30292818

Changes in bone density and bone turnover in patients with rheumatoid arthritis treated with rituximab, results from an exploratory, prospective study. Wheeler, G. et al. *PloS One*. 2018, 13(8), e0201527.

<https://doi.org/10.1371/journal.pone.0201527> PMID: 30080871; PMCID: PMC6078302

Circulating levels of sclerostin but not DKK1 associate with laboratory parameters of CKD-MBD. Behets, G. J. et al. *PLOS ONE*. 2017, 12(5), e0176411.

<https://doi.org/10.1371/journal.pone.0176411>

Serum serotonin levels and bone in rheumatoid arthritis patients. Bernardes, Miguel et al. *Rheumatology International*. 2017, 37(11), 1891–1898.

<https://doi.org/10.1007/s00296-017-3836-9>

Myocardial Perfusion in Rheumatoid Arthritis Patients: Associations with Traditional Risk Factors and Novel Biomarkers. Bernardes, Miguel et al. *BioMed Research International*. 2017, 2017, 1–9.

<https://doi.org/10.1155/2017/6509754>

Markers of bone metabolism during 14 days of bed rest in young and older men.

Buehlmeier, J. et al. 2017, 10.

Wnt antagonist sclerostin and Dickkopf-1 in gestational diabetes. Catalano, A. et al.

Diabetes & Metabolism. 2017, 43(4), 375–377.

<https://doi.org/10.1016/j.diabet.2016.09.009>

Serum levels of Dickkopf-1 are a potential negative biomarker of survival in geriatric patients. Dovjak, P. et al. *Experimental Gerontology*. 2017, 96, 104–109.

<https://doi.org/10.1016/j.exger.2017.06.002>

In psoriatic arthritis Dkk-1 and PTH are lower than in rheumatoid arthritis and healthy controls. Fassio, A. et al. *Clinical Rheumatology*. 2017, 36(10), 2377–2381.

<https://doi.org/10.1007/s10067-017-3734-2>

Adjuvant tamoxifen but not aromatase inhibitor therapy decreases serum levels of the Wnt inhibitor dickkopf-1 while not affecting sclerostin in breast cancer patients.

Göbel, A. et al. *Breast Cancer Research and Treatment*. 2017, 164(3), 737–743.

<https://doi.org/10.1007/s10549-017-4296-3>

Circulating Dickkopf-1 and sclerostin in patients with Paget's disease of bone.

Idolazzi, Luca et al. *Clinical Rheumatology*. 2017, 36(4), 925–928.

<https://doi.org/10.1007/s10067-016-3497-1>

Effects of short-term dry immersion on bone remodeling markers, insulin and adipokines. Linossier, M.-T. et al. *PLOS ONE*. 2017, 12(8), e0182970.

<https://doi.org/10.1371/journal.pone.0182970>

Long-Term Effects of Severe Burn Injury on Bone Turnover and Microarchitecture.

Muschitz, G. K. et al. *Journal of Bone and Mineral Research*. 2017, 32(12), 2381–2393.

<https://doi.org/10.1002/jbmr.3211>+ Condition: Severe burns#Sample type:

Serum#Conclusion: “In adult male patients, early and sustained changes of markers of bone resorption, formation+ and regul

ators of bone signaling pathways, prolonged inflammatory cytokine activities in conjunction with muscle catabolism and vitamin D insufficiency were observed. These alterations are directly linked to a prolonged deterioration of bone microstructure.”

Relationship between serum adipokine levels and radiographic progression in patients with ankylosing spondylitis: A preliminary 2-year longitudinal study. Park, J.-H. et al. *Medicine*. 2017, 96(33), e7854.

<https://doi.org/10.1097/MD.0000000000007854>

Ankylosing Spondylitis Patients Have Impaired Osteoclast Gene Expression in Circulating Osteoclast Precursors. Perpétuo, I. P. et al. *Frontiers in Medicine*. 2017, 4,

<https://doi.org/10.3389/fmed.2017.00005>

Effect of Tumor Necrosis Factor Inhibitor Therapy on Osteoclasts Precursors in Rheumatoid Arthritis. Perpétuo, I. P. et al. *BioMed Research International*. 2017, 2017,

1–10.

<https://doi.org/10.1155/2017/2690402>

Association between serum dickkopf-1 levels and disease duration in axial spondyloarthritis. Rubio Vargas, R. et al. *Reumatología Clínica*. 2017, 13(4), 197–200.

<https://doi.org/10.1016/j.reuma.2016.04.013>

A Cytokine-Like Protein Dickkopf-Related Protein 3 Is Atheroprotective. Yu, B. et al. *Circulation*. 2017, 136(11), 1022–1036.

<https://doi.org/10.1161/CIRCULATIONAHA.117.027690>

Effects of TNF Inhibitors on Parathyroid Hormone and Wnt Signaling Antagonists in Rheumatoid Arthritis. Adami, G. et al. *Calcified Tissue International*. 2016, 99(4), 360–364.

<https://doi.org/10.1007/s00223-016-0161-3>

Presence of HLA-B27 is associated with changes of serum levels of mediators of the Wnt and hedgehog pathway. Aschermann, S. et al. *Joint Bone Spine*. 2016, 83(1), 43–46.

<https://doi.org/10.1016/j.jbspin.2015.03.019>

Bone loss in patients with early inflammatory back pain suggestive of spondyloarthritis: results from the prospective DESIR cohort. Briot, K. et al. *Rheumatology*. 2016, 55(2), 335–342.

<https://doi.org/10.1093/rheumatology/kev332>

p38 MAPK regulates the Wnt inhibitor Dickkopf-1 in osteotropic prostate cancer cells. Browne, A. J. et al. *Cell Death & Disease*. 2016, 7(2), e2119–e2119.

<https://doi.org/10.1038/cddis.2016.32>

Effect of Osteoprotegerin and Dickkopf-Related Protein 1 on Radiological Progression in Tightly Controlled Rheumatoid Arthritis. Gómez-Vaquero, C. et al. *PLOS ONE*. 2016, 11(12), e0166691.

<https://doi.org/10.1371/journal.pone.0166691>

Serum Sclerostin as an Independent Marker of Peripheral Arterial Stiffness in Renal Transplantation Recipients: A Cross-Sectional Study. Hsu, B.-G. et al. *Medicine*. 2016, 95(15), e3300.

<https://doi.org/10.1097/MD.0000000000003300>

Changes of serum sclerostin and Dickkopf-1 levels during the menstrual cycle. A pilot study. Liakou, C. G. et al. *Endocrine*. 2016, 54(2), 543–551.

<https://doi.org/10.1007/s12020-016-1056-9> PMID: 27601021

Effects of strontium ranelate on bone mass and bone turnover in women with thalassemia major-related osteoporosis. Morabito, N. et al. *Journal of Bone and Mineral Metabolism*. 2016, 34(5), 540–546.

<https://doi.org/10.1007/s00774-015-0689-8>

The Impact of Vitamin D, Calcium, Protein Supplementation, and Physical Exercise on Bone Metabolism After Bariatric Surgery: The BABS Study: BONE METABOLISM AFTER BARIATRIC SURGERY (BABS). Muschitz, C. et al. *Journal of Bone and Mineral Research*. 2016, 31(3), 672–682.

<https://doi.org/10.1002/jbmr.2707>

Circulating sclerostin and Dickkopf-1 levels in patients with nonalcoholic fatty liver disease. Polyzos, Stergios A. et al. *Journal of Bone and Mineral Metabolism*. 2016, 34(4), 447–456.

<https://doi.org/10.1007/s00774-015-0687-x>

Higher Level of Dickkopf-1 is Associated with Low Bone Mineral Density and Higher Prevalence of Vertebral Fractures in Patients with Ankylosing Spondylitis. Rossini, M. et al. *Calcified Tissue International*. 2016, 98(5), 438–445.

<https://doi.org/10.1007/s00223-015-0093-3>

Increased Dickkopf-1 in Recent-onset Rheumatoid Arthritis is a New Biomarker of Structural Severity. Data from the ESPOIR Cohort. Seror, R. et al. *Scientific Reports*. 2016, 6(1).

<https://doi.org/10.1038/srep18421>

Epicardial fat is a negative predictor of spine volumetric bone mineral density and trabecular bone score in acromegaly. Valassi, E. et al. *Endocrine*. 2016, 53(3), 860–864.

<https://doi.org/10.1007/s12020-016-0945-2>

The effect of tocilizumab on bone mineral density, serum levels of Dickkopf-1 and bone remodeling markers in patients with rheumatoid arthritis. Briot, K. et al. *Joint Bone Spine*. 2015, 82(2), 109–115.

<https://doi.org/10.1016/j.jbspin.2014.10.015>

Strong relationship between vitamin D status and bone mineral density in anorexia nervosa. Gatti, D. et al. *Bone*. 2015, 78, 212–215.

<https://doi.org/10.1016/j.bone.2015.05.014>

Effect of Recent Spinal Cord Injury on Wnt Signaling Antagonists (Sclerostin and Dkk-1) and Their Relationship With Bone Loss. A 12-Month Prospective Study: RECENT SCI AND BONE LOSS. Gifre, Laia et al. *Journal of Bone and Mineral Research*. 2015, 30(6), 1014–1021.

<https://doi.org/10.1002/jbmr.2423>

Potentiated suppression of Dickkopf-1 in breast cancer by combined administration of the mevalonate pathway inhibitors zoledronic acid and statins. Göbel, A. et al. *Breast Cancer Research and Treatment*. 2015, 154(3), 623–631.

<https://doi.org/10.1007/s10549-015-3624-8>

Changes in Serum Levels of Myokines and Wnt-Antagonists after an Ultramarathon Race. Kerschman-Schindl, K. et al. *PLOS ONE*. 2015, 10(7), e0132478.

<https://doi.org/10.1371/journal.pone.0132478>

Diagnostic Accuracy of Bone Turnover Markers as a Screening Tool for Aseptic Loosening after Total Hip Arthroplasty. Lawrence, N. R. et al. *HIP International*. 2015, 25(6), 525–530.

<https://doi.org/10.5301/hipint.5000253>

High Parathyroid Hormone Level and Osteoporosis Predict Progression of Coronary Artery Calcification in Patients on Dialysis. Malluche, H. H. et al. *Journal of the American Society of Nephrology*. 2015, 26(10), 2534–2544.

<https://doi.org/10.1681/ASN.2014070686>

Sclerostin and DKK-1: two important regulators of bone metabolism in HIV-infected youths. Mora, S. et al. *Endocrine*. 2015, 49(3), 783–790.

<https://doi.org/10.1007/s12020-015-0527-8>

Osteoprotegerin and sclerostin in chronic kidney disease prior to dialysis: potential partners in vascular calcifications. Morena, M. et al. *Nephrology Dialysis Transplantation*. 2015, 30(8), 1345–1356.

<https://doi.org/10.1093/ndt/gfv081>

Ibandronate Increases Sclerostin Levels and Bone Strength in Male Patients with Idiopathic Osteoporosis. Muschitz, C. et al. *Calcified Tissue International*. 2015, 96(6), 477–489.

<https://doi.org/10.1007/s00223-015-0003-8>

Sclerostin Levels and Changes in Bone Metabolism After Bariatric Surgery. Muschitz, C. et al. *The Journal of Clinical Endocrinology & Metabolism*. 2015, 100(3), 891–901.

<https://doi.org/10.1210/jc.2014-3367>

Increase in Dickkopf-1 Serum Level in Recent Spondyloarthritis. Data from the DESIR Cohort. Nocturne, G. et al. *PLOS ONE*. 2015, 10(8), e0134974.

<https://doi.org/10.1371/journal.pone.0134974>

Dickkopf-1 and sclerostin serum levels in patients with systemic mastocytosis.

Rossini, M. et al. *Calcified Tissue International*. 2015, 96(5), 410–416.

<https://doi.org/10.1007/s00223-015-9969-5> PMID: 25694360

Serum fetuin-A levels and abdominal aortic calcification in healthy men — The STRAMBO study. Schoppet, M. et al. *Bone*. 2015, 79, 196–202.

<https://doi.org/10.1016/j.bone.2015.06.004>

Factors associated with serum soluble inhibitors of Wnt- β -catenin signaling (sclerostin and dickkopf-1) in patients undergoing peritoneal dialysis: Soluble Wnt- β -catenin inhibitors in PD. Yamada, S. et al. *Nephrology*. 2015, 20(9), 639–645.

<https://doi.org/10.1111/nep.12509>

Brief Report: Tumor Necrosis Factor and Interleukin-6 Differentially Regulate Dkk-1 in the Inflamed Arthritic Joint: EXPRESSION AND REGULATION OF Dkk-1 IN INFLAMED ARTHRITIC JOINTS. Yeremenko, N. et al. *Arthritis & Rheumatology*.

2015, 67(8), 2071–2075.

<https://doi.org/10.1002/art.39183>

Downregulation of serum DKK-1 predicts poor prognosis in patients with papillary thyroid cancer. Zhao, Y. P. et al. *Genetics and Molecular Research*. 2015, 14(4), 18886–18894.

<https://doi.org/10.4238/2015.December.28.38>

Serum sclerostin in high-activity adult patients with juvenile idiopathic arthritis.

Brabnikova-Maresova, K. et al. *Arthritis Research & Therapy*. 2014, 16(5).

<https://doi.org/10.1186/s13075-014-0460-x>

DKK-1 in prostate cancer diagnosis and follow up. D'Amelio, P. et al. *BMC Clinical Pathology*. 2014, 14(1).

<https://doi.org/10.1186/1472-6890-14-11>

Serum Levels of Sclerostin and Dickkopf-1: Effects of Age, Gender and Fracture Status. Dovjak, P. et al. *Gerontology*. 2014, 60(6), 493–501.

<https://doi.org/10.1159/000358303>

The Effect of Leptin Replacement on Parathyroid Hormone, RANKL-Osteoprotegerin Axis, and Wnt Inhibitors in Young Women With Hypothalamic Amenorrhea. Foo, J.-P. et al. *The Journal of Clinical Endocrinology & Metabolism*. 2014, 99(11), E2252–E2258.

<https://doi.org/10.1210/jc.2014-2491>

Relationship of Dickkopf1 (DKK1) with Cardiovascular Disease and Bone Metabolism in Caucasian Type 2 Diabetes Mellitus. Garcia-Martín, A. et al. *PLoS ONE*. 2014, 9(11), e111703.

<https://doi.org/10.1371/journal.pone.0111703>

Distinct effect of zoledronate and clodronate on circulating levels of DKK1 and sclerostin in women with postmenopausal osteoporosis. Gatti, D. et al. *Bone*. 2014, 67, 189–192.

<https://doi.org/10.1016/j.bone.2014.06.037>

The relationship between inhibitors of the Wnt signalling pathway (sclerostin and Dickkopf-1) and carotid intima-media thickness in postmenopausal women with type 2 diabetes mellitus. Gaudio, A. et al. *Diabetes and Vascular Disease Research*. 2014, 11(1), 48–52.

<https://doi.org/10.1177/1479164113510923>

Biomarkers of Bone Metabolism in Ankylosing Spondylitis in Relation to Osteoproliferation and Osteoporosis. Klingberg, E. et al. *The Journal of Rheumatology*. 2014, 41(7), 1349–1356.

<https://doi.org/10.3899/jrheum.131199>

Effect of aromatase inhibition on serum levels of sclerostin and dickkopf-1, bone turnover markers and bone mineral density in women with breast cancer. Kyvernitakis, I. et al. *Journal of Cancer Research and Clinical Oncology*. 2014, 140(10), 1671–1680.

<https://doi.org/10.1007/s00432-014-1726-z>

Role of Sclerostin and Dickkopf-1 in the Dramatic Alteration in Bone Mass Acquisition in Adolescents and Young Women With Recent Anorexia Nervosa. Maïmoun, L. et al. *The Journal of Clinical Endocrinology & Metabolism*. 2014, 99(4), E582–E590.

<https://doi.org/10.1210/jc.2013-2565>

Bone Mineral Density and Serum Biochemical Predictors of Bone Loss in Patients with CKD on Dialysis. Malluche, H. H. et al. *Clinical Journal of the American Society of Nephrology*. 2014, 9(7), 1254–1262.

<https://doi.org/10.2215/CJN.09470913>

Dickkopf-1 is regulated by the mevalonate pathway in breast cancer. Rachner, T. D. et al. *Breast Cancer Research*. 2014, 16(1).

<https://doi.org/10.1186/bcr3616>

High serum levels of Dickkopf-1 are associated with a poor prognosis in prostate cancer patients. Rachner, T. D. et al. *BMC Cancer*. 2014, 14(1).

<https://doi.org/10.1186/1471-2407-14-649>

Serum levels of sclerostin, Dickkopf-1, and secreted frizzled-related protein-4 are not changed in individuals with high bone mass causing mutations in LRP5. Simpson, C. A. et al. *Osteoporosis International*. 2014, 25(10), 2383–2388.

<https://doi.org/10.1007/s00198-014-2767-5>

VTD consolidation, without bisphosphonates, reduces bone resorption and is associated with a very low incidence of skeletal-related events in myeloma patients post ASCT. Terpos, E et al. *Leukemia*. 2014, 28(4), 928–934.

<https://doi.org/10.1038/leu.2013.267>

The combination of lenalidomide and dexamethasone reduces bone resorption in responding patients with relapsed/refractory multiple myeloma but has no effect on bone formation: Final results on 205 patients of the Greek myeloma study group.

Terpos, Evangelos et al. *American Journal of Hematology*. 2014, 89(1), 34–40.

<https://doi.org/10.1002/ajh.23577>

Comparative Effect of Zoledronic Acid Versus Denosumab on Serum Sclerostin and Dickkopf-1 Levels of Naive Postmenopausal Women With Low Bone Mass: A Randomized, Head-to-Head Clinical Trial. Anastasilakis, A. D. et al. *The Journal of Clinical Endocrinology & Metabolism*. 2013, 98(8), 3206–3212.

<https://doi.org/10.1210/jc.2013-1402>

Elevated Serum Dickkopf-1 Levels Increase Risk of Hip and Vertebral Fracture in Older Caucasian Women : Osteoporosis & Other Metabolic Bone Diseases. Arasu, A. et al. In *ENDO Meetings*. 2013.

Abgerufen von <http://press.endocrine.org/doi/abs/10.1210/endo-meetings.2013.BCHVD.9.SAT-224>

AB0243 Relationship between bone mineral density and radiographic damage in established rheumatoid arthritis patients under biologics. Bernardes, M. et al. In *Annals of the Rheumatic Diseases*. 2013 (Bd. 72, S. A861.2-A861).

<https://doi.org/10.1136/annrheumdis-2013-eular.2566>

High dickkopf-1 levels in sera and leukocytes from children with 21-hydroxylase deficiency on chronic glucocorticoid treatment. Brunetti, G. et al. *American Journal of Physiology-Endocrinology and Metabolism*. 2013, 304(5), E546–E554.

<https://doi.org/10.1152/ajpendo.00535.2012>

AB0059 Effect of anti-tnf alpha treatment on serum levels of light (tnfsf14), cathepsin k, dkk-1 and sclerostin in ankylosing spondylitis: the osteoclast/osteoblast function balance and its relation to disease activity. Cauli, A. et al. In *Annals of the Rheumatic Diseases*. 2013 (Bd. 72, S. A803.3-A803).

<https://doi.org/10.1136/annrheumdis-2013-eular.2382>

Genetic studies on components of the Wnt signalling pathway and the severity of joint destruction in rheumatoid arthritis. de Rooy, D. P. C. et al. *Annals of the Rheumatic Diseases*. 2013, 72(5), 769–775.

<https://doi.org/10.1136/annrheumdis-2012-202184>

Effect of glucocorticoid treatment on Wnt signalling antagonists (sclerostin and Dkk-1) and their relationship with bone turnover. Gifre, L. et al. *Bone*. 2013, 57(1), 272–276.

<https://doi.org/10.1016/j.bone.2013.08.016>

AB0614 Role of wnt antagonists (sclerostin and dkk-1) on bone turnover markers and bone mass, in patients with complete spinal cord injury. preliminary results. Gifre, L. et al. In *Annals of the Rheumatic Diseases*. 2013 (Bd. 72, S. A977.2-A977).

<https://doi.org/10.1136/annrheumdis-2013-eular.2936>

Sclerostin and DKK1 in Primary Hyperparathyroidism. Viapiana, O. et al. *Calcified Tissue International*. 2013, 92(4), 324–329.

<https://doi.org/10.1007/s00223-012-9665-7>

Sclerostin serum levels correlate positively with bone mineral density and microarchitecture in haemodialysis patients. Cejka, D. et al. *Nephrology Dialysis Transplantation*. 2012, 27(1), 226–230.

<https://doi.org/10.1093/ndt/gfr270>

Sclerostin and DKK1 in postmenopausal osteoporosis treated with denosumab. Gatti, D. et al. *Journal of Bone and Mineral Research*. 2012, 27(11), 2259–2263.

<https://doi.org/10.1002/jbmr.1681>

Sclerostin Levels Associated with Inhibition of the Wnt/ β -Catenin Signaling and Reduced Bone Turnover in Type 2 Diabetes Mellitus. Gaudio, A. et al. *The Journal of Clinical Endocrinology & Metabolism*. 2012, 97(10), 3744–3750.

<https://doi.org/10.1210/jc.2012-1901>

High level of functional dickkopf-1 predicts protection from syndesmophyte formation in patients with ankylosing spondylitis. Heiland, G. R. et al. *Annals of the Rheumatic Diseases*. 2012, 71(4), 572–574.

<https://doi.org/10.1136/annrheumdis-2011-200216>

High Circulating Levels of Sclerostin Correlate with Bone Mineral Density In Patients with Thalassemia and Osteoporosis: The Role of the Wnt Signaling In the Pathogenesis of Bone Loss In Thalassemia | Blood Journal. High Circulating Levels

of Sclerostin Correlate with Bone Mineral Density In Patients with Thalassemia and Osteoporosis: The Role of the Wnt Signaling In the Pathogenesis of Bone Loss In Thalassemia | Blood Journal. 2012.

Abgerufen von <http://www.bloodjournal.org/content/116/21/1010>

Serum Osteoprotegerin, RANKL, and Dkk-1 Levels in Adults with Langerhans Cell Histiocytosis. Makras, P. et al. *The Journal of Clinical Endocrinology & Metabolism*. 2012, 97(4), E618–E621.

<https://doi.org/10.1210/jc.2011-2962>

Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women--the six-month effect of risedronate and teriparatide.

Polyzos, S. A. et al. *Osteoporosis International: A Journal Established as Result of Cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA*. 2012, 23(3), 1171–1176.

<https://doi.org/10.1007/s00198-010-1525-6> PMID: 21305266

Low circulating Dickkopf-1 and its link with severity of spinal involvement in diffuse idiopathic skeletal hyperostosis. Senolt, L. et al. *Annals of the Rheumatic Diseases*. 2012, 71(1), 71–74.

<https://doi.org/10.1136/annrheumdis-2011-200357>

Biomarkers and cytokines of bone turnover: extensive evaluation in a cohort of patients with ankylosing spondylitis. Taylan, A. et al. *BMC Musculoskeletal Disorders*. 2012, 13, 191.

<https://doi.org/10.1186/1471-2474-13-191> PMID: 23025387; PMCID: PMC3492209

High circulating sclerostin is present in patients with thalassemia-associated osteoporosis and correlates with bone mineral density. Voskaridou, E. et al. *Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme*. 2012, 44(12), 909–913.

<https://doi.org/10.1055/s-0032-1312618> PMID: 22581647

Sclerostin and Dickkopf-1 in Renal Osteodystrophy. Cejka, D. et al. *Clinical Journal of the American Society of Nephrology*. 2011, 6(4), 877–882.

<https://doi.org/10.2215/CJN.06550810>

Serum Levels of Glycoprotein Dickkopf-1 in Patients with Cutaneous Malignant Melanoma: A Prospective Pilot Study. Feldmann, R. et al. *Dermatology*. 2011, 222(2), 171–175.

<https://doi.org/10.1159/000324516>

Levels of serotonin, sclerostin, bone turnover markers as well as bone density and microarchitecture in patients with high-bone-mass phenotype due to a mutation in Lrp5. Frost, M. et al. *Journal of Bone and Mineral Research*. 2011, 26(8), 1721–1728.

<https://doi.org/10.1002/jbmr.376>

The Waning of Teriparatide Effect on Bone Formation Markers in Postmenopausal Osteoporosis Is Associated with Increasing Serum Levels of DKK1. Gatti, D. et al. *The Journal of Clinical Endocrinology & Metabolism*. 2011, 96(5), 1555–1559.

<https://doi.org/10.1210/jc.2010-2552>

Bone microstructural changes revealed by high-resolution peripheral quantitative computed tomography imaging and elevated DKK1 and MIP-1 levels in patients with MGUS. Ng, A. C. et al. *Blood*. 2011, 118(25), 6529–6534.

<https://doi.org/10.1182/blood-2011-04-351437>

Early effects of IL-6 receptor inhibition on bone homeostasis: a pilot study in women with rheumatoid arthritis. Terpos, Evangelos et al. *Clinical and Experimental Rheumatology*. 2011, 29(6), 921–925.

PMID: 22032557

Increased Sclerostin Serum Levels Associated with Bone Formation and Resorption Markers in Patients with Immobilization-Induced Bone Loss. Gaudio, A. et al. *The Journal of Clinical Endocrinology & Metabolism*. 2010, 95(5), 2248–2253.

<https://doi.org/10.1210/jc.2010-0067>

Circulating Levels of the Wnt Inhibitors Dickkopf-1 and Sclerostin In Different Phases of Multiple Myeloma: Alterations Post-Therapy with Lenalidomide and Dexamethasone with or without Bortezomib. Terpos, Evangelos et al. *Blood*. 2010, 116(21), 2963–2963.

Abgerufen von <http://www.bloodjournal.org/content/116/21/2963>

High Circulating Levels of Sclerostin Correlate with Bone Mineral Density In Patients with Thalassemia and Osteoporosis: The Role of the Wnt Signaling In the Pathogenesis of Bone Loss In Thalassemia. Voskaridou, Ersi et al. In *Blood*. 2010 (Bd. 116, S. 1010–1010).

Abgerufen von <http://www.bloodjournal.org/content/116/21/1010>

The Effect of Zoledronic Acid on Serum Dickkopf-1, Osteoprotegerin, and RANKL in Patients with Paget’s Disease of Bone. Polyzos, S. A. et al. *Hormone and Metabolic Research*. 2009, 41(11), 846–850.

<https://doi.org/10.1055/s-0029-1233491>

High Serum Sclerostin Correlates with Advanced Stage, Increased Bone Resorption, Reduced Osteoblast Function, and Poor Survival in Newly-Diagnosed Patients with Multiple Myeloma. Terpos, Evangelos et al. 2009.

Opposite relationships between circulating Dkk-1 and cartilage breakdown in patients with rheumatoid arthritis and knee osteoarthritis. Voorzanger-Rousselot, N et al. *Annals of the Rheumatic Diseases*. 2009, 68(9), 1513–1514.

<https://doi.org/10.1136/ard.2008.102350>

Assessment of Circulating Dickkopf-1 with a New Two-Site Immunoassay in Healthy Subjects and Women with Breast Cancer and Bone Metastases. Voorzanger-Rousselot, Nathalie et al. *Calcified Tissue International*. 2009, 84(5), 348–354.

<https://doi.org/10.1007/s00223-009-9225-y>

Serum Dickkopf-1 is increased and correlates with reduced bone mineral density in patients with thalassemia-induced osteoporosis. Reduction post-zoledronic acid administration. Voskaridou, Ersi et al. 2009, 4.

Circulating Dickkopf-1 and Radiological Progression in Patients with Early Rheumatoid Arthritis Treated with Etanercept. Garnero, P. et al. *The Journal of Rheumatology*. 2008, 35(12), 2313.

<https://doi.org/10.3899/jrheum.080356>

Glucocorticoids Attenuate the Stimulatory Effect on Bone Formation by Bortezomib. Lund, T. et al. 2008.

Osteoclasts Are Active in Bone Forming Metastases of Prostate Cancer Patients. Roato, I. et al. *PLoS ONE*. 2008, 3(11), e3627.

<https://doi.org/10.1371/journal.pone.0003627>